Table 3.
Anti-Vi IgG antibody immunogenicity before vaccination (day 0) and 28 days after vaccination.
| Group 1 TCV + IPV (delayed MCV-A) |
Group 2 TCV + MCV-A |
Group 3 MCV-A + IPV |
|
|---|---|---|---|
| (n = 48)a | (n = 50) | (n = 51) | |
| Seroconversion (≥4-fold rise from day 0 to 28 days after vaccination) | 44b (93.6%, 82.5–98.7%) | 48 (96.0%, 86.3–99.5%) | 2 (3.9, 0.5–13.5%) |
| Day 0 geometric mean titre | 5.0 (4.0–6.3) | 4.7 (3.7–5.8) | 4.8 (3.8–6.2) |
| Day 28 geometric mean titre | 2754.1b (1537.3–4934.1) | 3707.3 (2632.0–5222.0) | 5.3 (4.1–6.9) |
Data are n (%, 95% confidence interval) or mean (95% confidence interval). n = number of participants. IPV, inactivated polio vaccine; MCV-A, group A meningococcal conjugate vaccine; TCV, typhoid conjugate vaccine.
a
One participant excluded in per-protocol immunogenicity analysis for late day 28 visit.
b
One participant missing titre, n = 47.